Financials data is unavailable for this security.
View more
Year on year Supernus Pharmaceuticals Inc 's revenues fell -8.95% from 667.24m to 607.52m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 60.71m to 1.32m, a -97.83% decrease.
| Gross margin | 89.04% |
|---|---|
| Net profit margin | 9.16% |
| Operating margin | 9.09% |
| Return on assets | 4.54% |
|---|---|
| Return on equity | 6.22% |
| Return on investment | 5.83% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Supernus Pharmaceuticals Inc fell by 18.07m. However, Cash Flow from Investing totalled 268.73m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 111.09m in cash from operations while cash used for financing totalled 397.88m.
| Cash flow per share | 2.57 |
|---|---|
| Price/Cash flow per share | 13.84 |
| Book value per share | 18.24 |
|---|---|
| Tangible book value per share | 6.34 |
More ▼
Balance sheet in USDView more
| Current ratio | 2.20 |
|---|---|
| Quick ratio | 1.98 |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items dropped -97.72%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
| EPS growth(5 years) | -59.02 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 147.69 |
